Log In
Print this Print this

sitravatinib (MGCD516) (formerly MG516)

  Manage Alerts
Collapse Summary General Information
Company Mirati Therapeutics Inc.
DescriptionSmall molecule inhibitor of tyrosine kinase receptor, ret proto-oncogene (RET) and discoidin domain receptor tyrosine kinase (DDR)
Molecular Target Ret proto-oncogene (RET)
Mechanism of ActionKinase inhibitor; RET inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat advanced solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today